Name | SLx-2119 |
Synonyms | KD-025 SLx2119 SLx 2119 SLX-2119 SLx-2119 ROCK INHIBITOR ROCK inhibitor 2 KD025 (SLx-2119) 2-[3-[4-[(1H-Indazol-5-yl)amino]quinazolin-2-yl]phenoxy]-N-isopropylacetamide |
CAS | 911417-87-3 |
Molecular Formula | C26H24N6O2 |
Molar Mass | 452.51 |
Density | 1.318±0.06 g/cm3(Predicted) |
Melting Point | >228oC (dec.) |
Boling Point | 682.6±55.0 °C(Predicted) |
Solubility | Soluble in DMSO (25 mg/ml) |
Appearance | solid |
Color | White |
pKa | 13?+-.0.40(Predicted) |
Storage Condition | 2-8°C(protect from light) |
Stability | Stable for 1 year as supplied from date of purchase. Solutions in DMSO may be stored at -20°C for up to 1 month. |
In vitro study | Kdo25 reduced secretion by IL-17 and IL-21 in human PBMC cells and decreased phosphorylation of STAT3 and expression of IRF4 and Rorγt in CD4 T cells. In human peripheral blood mononuclear cells, kdo25 inhibited the secretion of IL-21,IL-17 and IFNγ, while reducing the expression of phosphorylated STAT3 and IRF4 and bcl6. |
In vivo study | In mice, kdo25 (200 mg/kg, p.o.) reduced ROCK activity in brain and heart. Kdo25 (200 mg/kg, p.o.) significantly reduced the area of the perfusion defect and reduced the damage to the ipsilateral hemisphere. In a mouse model of collagen-induced arthritis, kdo25 (200 mg/kg, I. p.) reduced the development of arthritis by acting on the Th17 mediated signaling pathway. Kdo25 (150 mg/kg, I. p. or p. o.) was effective in ameliorating chronic graft-versus-host disease in a murine model of obliterative bronchitis syndrome and scleroderma. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.21 ml | 11.049 ml | 22.099 ml |
5 mM | 0.442 ml | 2.21 ml | 4.42 ml |
10 mM | 0.221 ml | 1.105 ml | 2.21 ml |
5 mM | 0.044 ml | 0.221 ml | 0.442 ml |